Editas Medicine Financials - Benzinga

Editas Medicine Inc

EDITNASDAQ

Trade with Public

Trade with Public

$2.58

-0.17-6.18%

近くで: Sep 25, 5:00 PM EST

$2.59

0.010.39%

時間外: 6:26 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Editas Medicine Financials

Editas Medicine (EDIT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from

Benzinga Newsdesk

PRO
Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of $(0.43) per share from

Benzinga Newsdesk

Editas Medicine Q4 Earnings Assessment

Benzinga Insights

PRO
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of $(0.40) per share from the

Benzinga Newsdesk

PRO
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from

Benzinga Newsdesk

PRO
Editas Medicine Q2 EPS $(0.63) Misses $(0.38) Estimate, Sales $3.578M Beat $1.666M Estimate

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved